Targeted pharmaceuticals and ligands
OwnerJohn L. Muschler, Dmitri B. Kirpotin +1inventors
InventorsJohn L. Muschler, Dmitri B. Kirpotin, Daryl C. Drummond
Life of this patent
Estimating the term…
Abstract
The disclosure pertains to pharmaceuticals, more specifically, to targeted diagnostic and therapeutic formulations and ligands thereof. Such methods and composition comprise antigens that are post-translationally modified compared to antigens found on a normal cell phenotype. Also provided are ligands that bind to such post-translationally modified antigens.
Claims46
A composition comprising a pharmaceutical entity linked to a ligand wherein the ligand specifically binds to a post-translationally modified antigen (PTMA).
A method of identifying a ligand that interacts with a post-translationally modified antigen (PTMA) comprising:
- (a) contacting a ligand library having a plurality of members with cells that display the PTMA, and
- (b) separating the cells from the library members that do not associate with the cells.
A method of identifying a ligand that interacts with a post-translationally modified antigen (PTMA) comprising:
- (a) contacting a ligand library having a plurality of members with cells of a first cell line that displays a precursor antigen;
- (b) separating the ligand library members that do not associate with the cells of the first cell line;
- (c) contacting the ligand display library members separated in (b) with the cells of the second cell line wherein the second cell line is obtained by a process comprising inducing the first cell line to modify the precursor antigen into the post-translationally modified antigen.
A ligand that binds to a post-translationally modified antigen (PTMA) expressed on the outer surface of a cell, and further internalizes into said cell.
Dependencies are inferred from the claim text.